CN1323662C - Pharmaceutical composition containing ambroxol and erdosteine or acetylcysteine and application thereof - Google Patents
Pharmaceutical composition containing ambroxol and erdosteine or acetylcysteine and application thereof Download PDFInfo
- Publication number
- CN1323662C CN1323662C CNB2005100775504A CN200510077550A CN1323662C CN 1323662 C CN1323662 C CN 1323662C CN B2005100775504 A CNB2005100775504 A CN B2005100775504A CN 200510077550 A CN200510077550 A CN 200510077550A CN 1323662 C CN1323662 C CN 1323662C
- Authority
- CN
- China
- Prior art keywords
- ambroxol
- erdosteine
- acetylcysteine
- pharmaceutical composition
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960005174 ambroxol Drugs 0.000 title claims description 96
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 title claims description 96
- QGFORSXNKQLDNO-UHFFFAOYSA-N erdosteine Chemical compound OC(=O)CSCC(=O)NC1CCSC1=O QGFORSXNKQLDNO-UHFFFAOYSA-N 0.000 title claims description 88
- 229960003262 erdosteine Drugs 0.000 title claims description 87
- 229960004308 acetylcysteine Drugs 0.000 title claims description 31
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 19
- 239000003814 drug Substances 0.000 claims description 39
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 210000002345 respiratory system Anatomy 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000003172 expectorant agent Substances 0.000 claims description 9
- 230000003419 expectorant effect Effects 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 48
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 36
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 35
- 206010011224 Cough Diseases 0.000 description 28
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 229940079593 drug Drugs 0.000 description 21
- 230000003203 everyday effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 206010036790 Productive cough Diseases 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 230000003248 secreting effect Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 12
- 208000024794 sputum Diseases 0.000 description 12
- 210000003802 sputum Anatomy 0.000 description 12
- 229910021529 ammonia Inorganic materials 0.000 description 11
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 10
- 208000026435 phlegm Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000029058 respiratory gaseous exchange Effects 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 206010006451 bronchitis Diseases 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 5
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical group [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 206010006458 Bronchitis chronic Diseases 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000007451 chronic bronchitis Diseases 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000004081 cilia Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical class C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- -1 acetylcysteine compound Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a medicinal composition containing ambroxol and erdosteine or medicinal salts of ambroxol and erdosteine and an application thereof, a medicinal composition containing ambroxol and acetylcysteine or medicinal salts of ambroxol and acetylcysteine and an application thereof, medicinal boxes containing the compositions, and an application of the medical composition to prepare expectorant medicine. The present invention also relates to mixed or synergistic combinations of ambroxol and erdosteine, and ambroxol and acetylcysteine; the synergistic combinations are used for treating sputum ropiness, difficult expectoration, stagnation of sputum in the trachea, etc. caused by diseases such as chronic bronchitis, bronchial asthma, etc. The synergistic combinations can also be used for preventing and treating the complication of difficult expectoration and pneumonitis because of operations.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and application thereof, described pharmaceutical composition contains the two officinal salt of ambroxol and erdosteine or its, described pharmaceutical composition can also contain ambroxol and acetylcysteine or the officinal salt of the two, and such drug regimen is used for preparing control respiratory tract congested and the various inflammation of infection and the application of the medicine of relevant diseases such as eliminating the phlegm, the application of the aspect of particularly eliminating the phlegm.
Background technology
Ambroxol is the active metabolite of bromhexine, and its toxicity is low, determined curative effect, and phlegm-dispelling functions is stronger than bromhexine, and this medicine is used for clinical the form with hydrochlorate in 1984.Ambroxol hydrochloride is widely used in the treatment respiratory system disease in states such as many countries such as the U.S., Britain, German Japan, and clinical effectiveness is good, almost non-toxic side effect.Ambroxol hydrochloride is widely used in acute, the chronic respiratory tract disease with sputum diacrisis and expectoration dysfunction clinically, the for example prophylactic treatment and the auxiliary treatment of acute/chronic bronchitis, asthmatic bronchitis, bronchiectasis and san bronchial asthma, pulmonary surgery patient's postoperative lung symphony complication, the thick sputum that lung structure etc. cause, the treatment of dys-expectoration and premature infant and new-born baby respiratory distress syndrome (IRDS).
Ambroxol hydrochloride oral absorbs rapidly, eliminates half-life 2～3hr, and its dosage form mainly contains tablet, sustained-release micro-pill capsules, solution, syrup, aqueous injection and other compound preparation, but, make its preparation application and clinical practice all be subjected to certain limitation because the water solublity of ambroxol hydrochloride is not ideal.
Erdosteine is a kind of prodrug, the sulfydryl that has non-free sealing in its structure, to local mucin inactive, oral after metabolism produces three and contains the metabolite of free sulfhydryl groups and bring into play pharmacological action, thereby the no obvious gastrointestinal side effect in oral back.Experimental results show that; the erdosteine cylinder metabolism-ure can make mucinous disulfide bonds in the bronchial secretion; and change secretions is formed and rheological property; reduce expectorant viscosity; improve downtrod respiratory function; this product can be removed free radical, effectively protects the anti-Trypsin undergraduate course of α 1-to avoid the oxidation deactivation that cigarette, dirt bring out, and prevents the damage to elastance of lung albumen and neutrophilic granulocyte.This product can also obviously increase IgA/ albumin, lactoferrin/albuminous ratio, weakens local inflammation, increases and improve the osmosis of antibiotic to bronchial mucosa, helps the treatment of the various inflammation of respiratory tract.
The phlegm dissolving expectorant that acetylcysteine is the most frequently used, the clinical suction in order to spraying is main.
We find pleasantly surprisedly, and ambroxol and erdosteine or ambroxol and acetylcysteine compound recipe are united use, and drug effect strengthens, and toxicity reduces.
Summary of the invention
There is wonderful discovery in the present application people, ambroxol and erdosteine, and the drug regimen of ambroxol and acetylcysteine can provide useful especially phlegm-dispelling functions, and does not observe side effect.And this class drug regimen is particularly suitable for treating, and the congested and various inflammation that infect of respiratory tract such as expectorant such as chronic bronchitis, asthma are sticking is difficult for the expectoration patient.
An object of the present invention is to provide two kinds and be used for controlling in advance the new drug regimen of expectorant, described drug regimen comprises that order gives or give simultaneously the ambroxol and the erdosteine of pharmaceutically acceptable amount, the two medicine of ambroxol and acetylcysteine or its can be accepted form, wherein, consumption every day of ambroxol is 1-2000mg, consumption every day of erdosteine is 1-2000mg, and consumption every day of acetylcysteine is 1-2000mg.
Administration simultaneously comprises and gives ambroxol and erdosteine or ambroxol and acetylcysteine, perhaps with the independent preparation administration simultaneously basically of every kind of activating agent.
Should be appreciated that ambroxol and erdosteine, ambroxol and acetylcysteine be respectively with its pharmaceutically acceptable form as the pharmaceutically active agents administration, its pharmaceutically acceptable form comprises pharmaceutically acceptable salt, ester and solvate.
" pharmaceutically acceptable " of the present invention comprises people and veterinary purpose.
For fear of query, the scalar of the ambroxol of the pharmaceutically acceptable form that the present invention provides or erdosteine or acetylcysteine, when comprising the mg amount, this scalar provides about chemical compound itself: for example the ambroxol of 50mg hydrochloride form is meant the amount of the hydrochlorate that contains the 50mg ambroxol; For example the erdosteine of 200mg hydrochloride form is meant the amount of the hydrochlorate of the erdosteine that contains 200mg.
A particular aspects, this drug regimen comprises the ambroxol that gives 1-2000mg every day.Particularly, this drug regimen comprises the ambroxol that gives 1-500mg, 500-1000mg or 1000-2000mg every day.Preferably, this drug regimen comprises the ambroxol that gives 100-1000mg every day.
A particular aspects, this drug regimen comprises the erdosteine that gives 1-2000mg every day.Particularly, this drug regimen comprises the erdosteine that gives 1-500mg, 500-1000mg or 1000-2000mg every day.Preferably, this drug regimen comprises the erdosteine that gives 1-1000mg every day.
A particular aspects, this drug regimen comprises the acetylcysteine that gives 1-2000mg every day.Particularly, this drug regimen comprises the acetylcysteine that gives 1-500mg, 500-1000mg or 1000-2000mg every day.Preferably, this drug regimen comprises the acetylcysteine that gives 1-1000mg every day.
The present invention proves by experiment, ambroxol and erdosteine, available useful especially control respiratory tract hyperemia of the drug regimen of ambroxol and acetylcysteine and inflammation such as the dys-expectoration effects of infecting such as chronic bronchitis, asthma, and show with respect to the synergism that contrasts, described contrast is contemplated to the effect summation of independent active agents.
Phlegm-dispelling functions can utilize conventional method to describe its feature, for example by measuring the increase of expectoration amount.
One preferred aspect, the dosage level of two kinds of activating agents of drug regimen of the present invention will less than reach add merely and the needed dosage of phlegm-dispelling functions.
In the present invention, active medicine is preferably with the form administration of pharmaceutical composition, and is as implied above, and two kinds of compositionss can comprise multiple medicine or only a kind of medicine.Therefore, another object of the present invention provides a kind of pharmaceutical composition, said composition contains the erdosteine of the ambroxol of 1-2000mg and 1-2000mg or contains the ambroxol of 1-2000mg and acetylcysteine or its two pharmaceutically acceptable salt of 1-2000mg, and pharmaceutically acceptable carrier.
In other words, the present invention relates to a kind of various inflammation that respiratory tract is congested and infect that are used to prevent and treat, be used for the expectorant pharmaceutical composition, described pharmaceutical composition comprises that order gives or give simultaneously ambroxol and the erdosteine or the acetylcysteine of pharmaceutically acceptable form, wherein, the content of ambroxol is 1-2000mg, and the content of erdosteine is 1-2000mg, and the content of acetylcysteine is 1-2000mg.
Described ambroxol is alkali or its officinal salt.The dosage form of pharmaceutical composition of the present invention is injection, injectable powder, spray, tablet, slow releasing agent, drop pill, granule, capsule, solution or slow-release micro-pill.
This shows that the present invention also provides the application of a kind of pharmaceutical composition of the present invention in preparation expectorant medicine.
The present composition can by with 1-2000mg ambroxol and 1-2000mg erdosteine or contain the ambroxol of 1-2000mg and the acetylcysteine of 1-2000mg or its two pharmaceutically acceptable salt with after pharmaceutically acceptable carrier mixes, prepared according to the preparation method of routine.
Usually this based composition is suitable for oral administration and drug administration by injection, also is fit to other medication, for example percutaneous dosing.
Said composition can be tablet, capsule, powder, spray, granule, lozenge, suppository, or oral administration solution or liquid preparation forms such as aseptic parenteral solution or suspension.
Said composition can be big or dosage forms such as small-volume injection, freeze-dried powder, aseptic powder packing.
In order to reach the concordance of administration, the present composition is preferably single agent form.
The single agent representation that is used for oral administration can be tablet and capsule, and can contain conventional excipients such as binding agent, for example syrup, arabic gum, gelatin, sorbitol, tragacanth or polyvinylpyrrolidone; Filler, for example lactose, sugar, corn starch, calcium phosphate, sorbitol or glycine; Tabletting lubricant, for example magnesium stearate; Disintegrating agent, for example starch, polyvinylpyrrolidone, Explotab or microcrystalline Cellulose; Or pharmaceutically acceptable wetting agent, such as sodium lauryl sulphate.
These compositionss are preferably to make unit dose with the amount that relevant daily dose suits.The unit dose of suitable ambroxol comprises the various dosage of 1-2000mg.Can the administration every day 1-6 time, but most preferably administration every day 1 time (drug administration by injection) or 3 times (oral administration).
The suitable dose of erdosteine comprises the various dosage that give 1-2000mg every day, but most preferably administration every day 1 time (drug administration by injection) or 3 times (oral administration).
The suitable dose of acetylcysteine comprises the various dosage that give 1-2000mg every day, but most preferably administration every day 1 time (drug administration by injection) or 3 times (oral administration).
Solid oral composition can prepare with conventional mixing, filling or pressed disc method.Repeating married operation can be used for activating agent fully is distributed to the compositions of using a large amount of filling doses.Conventional in such operation yes this area.Tablet can make coated tablet or plain sheet according to conventional preparation method.
Oral liquid can be the form of example emulsion, syrup or elixir, perhaps can be used as dry products and exists, and water or other suitable carriers reconstitute again before the use.This liquid preparation can contain conventional additives, such as suspending agent, and for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat; Emulsifying agent, for example lecithin, anhydro sorbitol-oleate or arabic gum; Anhydrous carrier (can comprise edible oil), for example almond oil, heating up in a steamer Oleum Cocois or oily ester, described oily ester comprises glyceride, propylene glycol or ethanol; Antiseptic, for example methyl parahydroxybenzoate or propyl ester or sorbic acid; If desired, also can add conventional flavoring agent or coloring agent.
For parenteral, particularly injection can utilize two kinds of active components to prepare the unit liquid dosage form with sterile carrier respectively, and according to used concentration with its suspension or be dissolved in the carrier.When preparation solution, active component can be dissolved in water for injection and filtration sterilization, be filled in bottle or the ampoule afterwards and sealing.Advantageously, adjuvant such as local anesthetic, antiseptic and buffer agent can be dissolved in this carrier.For enhanced stability, recharge in the bottle after can be with said composition freezing, and under vacuum, remove moisture.The parenteral suspension is to prepare and get with identical in fact mode, and just active component is not to be dissolved in the carrier, but is suspended in the carrier, and sterilizes and be not accomplished by filtration.This active component can be by with after oxirane contacts, and resuspending is in sterile carrier and sterilize.Advantageously, in said composition, comprise surfactant or wetting agent to promote this chemical compound uniform distribution.
In addition, also can single active ingredient or pharmaceutical composition in the drug regimen be made sustained-release preparation, as slow-release micro-pill or controlled release micro pill according to conventional method.
According to different medications, compositions can contain 0.1%-99% weight, the active substance of preferred 1-60% weight.
Therefore, the invention still further relates to ambroxol and erdosteine, ambroxol and acetylcysteine add and or cooperative compositions, these cooperative compositions are used for thick sputum, the difficulty of coughing up phlegm and the stagnation of phlegm trachea etc. that diseases such as chronic bronchitis, bronchial asthma cause, also can be used for cough up phlegm after control is performed the operation difficulty and pneumonia complication.
The present invention can also relate to a kind of medicine box, it is characterized in that it contains ambroxol, erdosteine, acetylcysteine, or their pharmaceutically acceptable salt, wherein, the content of ambroxol is 1-2000mg, the content of erdosteine is 1-2000mg, and the content of acetylcysteine is 1-2000mg.The patient uses the interior described medicine of medicine box to reach the purpose of using the present composition in order and/or simultaneously.
Following examples are in order to further elaboration the present invention, and do not play any restriction.
Description of drawings
Fig. 1 is the influence of compound recipe erdosteine ambroxol (etc. quality) to the phenol red secretion test in mouse breathing road.
The specific embodiment
The phenol red excretory influence in 1 pair of mouse breathing road of experimental example
1), test method
With 360 healthy male mices, be divided into 12 groups at random, be respectively negative control group, erdosteine group, compound recipe erdosteine ambroxol (etc. quality) 6 dosage groups, the basic, normal, high dosage group of ambroxol hydrochloride and potassium iodide groups.Every day, the oral test sample was 1 time, and continuous oral 3 days, administration volume are 0.4ml/20g, and negative control group is oral with the volume normal saline.Last administration fasting in preceding 1 day, 0.5 hour lumbar injection 2.5% phenol red solution 500mg/kg after the last administration, 0.4ml/20g.Give excessive anesthetics again after 0.5 hour and put to death animal, separate trachea, insert entry needle, use the 2ml normal saline flushing, flushing liquor adds 1M NaOH 0.1ml colour developing, in 546nm wavelength colorimetric, calculates phenol red content with 722 type spectrophotometers.
2), statistical analysis
(x ± s) expression, check with t by the statistical analysis of data with mean ± standard deviation for all data
3), result of the test
Result of the test sees the following form
Result of the test shows, compares with negative control group, and compound recipe erdosteine ambroxol (etc. quality) be though 2mg/kg dosage group oral administration can increase the phenol red secretory volume in mouse breathing road in 3 days, no difference of science of statistics (P＞0.05); 4mg/kg dosage group and normal saline group P value=0.058 relatively, further each group of increase dosage is compared with the feminine gender group and all can be increased the phenol red secretory volume in mouse breathing road (P＜0.01) very significantly, and compound recipe erdosteine ambroxol (etc. quality) 16mg/kg increases excretory effect with the ambroxol hydrochloride of dosage group and strengthens (P＜0.01) significantly, the action intensity of dosage 16 and 32mg/kg is close, when dosage increases to 64mg/kg secretion increase effect is shown downward trend (seeing figure).It is the strongest that the KI group increases the phenol red secretory volume effect in mouse breathing road, it increases each dosage group of effect and ambroxol hydrochloride of the phenol red secretory volume in mouse breathing road and compound recipe erdosteine ambroxol (etc. quality) 2mg/kg, 4mg/kg organizes and compares that all there were significant differences (P＜0.05), but with compound recipe erdosteine ambroxol (etc. quality) 8mg/kg, 16mg/kg, the 32mg/kg difference (P＞0.05) of comparing with 64mg/kg dosage group that there are no significant.
Test specimen is to the phenol red excretory influence in mouse breathing road (x ± s)
| Sample | Number of animals n | Dosage mg/kg | Phenol red amount (μ g/ml) | Increase percentage rate |
| (±SD) | ％ | |||
| Physiological saline KI Erdosteine compound Erdosteine ambroxol (etc. quality) | 30 30 30 30 30 30 30 30 30 30 30 30 | 20ml/kg 5000 40 2 4 8 16 32 64 16 32 64 | 0.72±0.17 1.10±0.25 ** 1.00±0.24 ** 0.80±0.20 0.84±0.21 a 1.00±0.25 ** 1.04±0.24 ##** 1.05±0.20 ** 0.99±0.21 ** 0.89±0.19 ** 0.93±0.27 ** 0.96±0.29 ** | - 52.8 38.5 10.5 14.7 38.6 44.8 45.6 37.6 22.9 29.2 32.5 |
*P＜0.05,
*Compare with the normal saline group P＜0.01;
#P＜0.05,
##The ambroxol hydrochloride group of P＜0.01 and Isodose relatively;
4), conclusion
Referring to Fig. 1, result of the test shows, each administration group all can increase the phenol red secretory volume in mouse breathing road, compare with the feminine gender group, KI, erdosteine, compound recipe erdosteine ambroxol (etc. quality) 8mg/kg, 16mg/kg, 32mg/kg, each dosage group oral administration of 64mg/kg dosage group and ambroxol hydrochloride all can increase the phenol red secretory volume in mouse breathing road by highly significant in 3 days, erdosteine wherein, compound recipe erdosteine ambroxol (etc. quality) 8mg/kg, 16mg/kg, 32mg/kg, the increase secretory action of 64mg/kg dosage group is compared with positive group KI, do not have significant difference statistically, and compound recipe erdosteine ambroxol (etc. quality) to increase excretory effect strong than the ambroxol hydrochloride of Isodose.
2 pairs of excretory influences of rabbit sputum of experimental example
1), experimental technique
With 80 of rabbit, be divided into 8 groups at random, be respectively compound recipe erdosteine ambroxol (mass ratio 2: 1) 1,2,4 and four dosage groups of 8mg/kg and ambroxol hydrochloride 2,4 and three dosage groups of 8mg/kg and negative control group and erdosteine 4mg/kg group.Animal is used the urethane intraperitoneal anesthesia, plugs endotracheal tube, constantly provides preheating (37 ℃) to be connected with the device of constant humidity (80%) breathe air with one.Lower end in the cross tracheal intubation connects a graduated cylinder that fixes, and is used to collect secretions.For preventing to produce condensed water, adopt a device that separates with Cotton Gossypii, all animals all freely breathe and guarantee the breathe air amount that it is required.Through 2 hours stable observation, will test medicine and deliver to stomach through esophagus.Collect 3 hours secretions after the administration immediately continuously, measure secretory volume.Calculate the excretory rate of change of sputum.
2), statistical analysis
(x ± s) expression, check with t by the statistical analysis of data with mean ± standard deviation for all data.
3), result of the test
Result of the test sees the following form
Result of the test shows, compare with negative control group, compound recipe erdosteine ambroxol (mass ratio 2: 1) 1,2,4 and four dosage groups of 8mg/kg and erdosteine 4mg/kg oral administration all can obviously increase rabbit respiratory tract sputum secretory volume, compound recipe erdosteine ambroxol (mass ratio 2: 1) 1mg/kg compares P＜0.05 with the feminine gender group, other each dosage group is compared the P value all＜0.01 with the feminine gender group, and the short sputum secretory action and the dosage of compound recipe erdosteine ambroxol (mass ratio 2: 1) are tangible positive correlation.Ambroxol hydrochloride also can obviously promote the secretion of rabbit respiratory tract sputum in dose dependent ground, but a little less than the compound recipe erdosteine ambroxol (mass ratio 2: 1) of effect than Isodose.
4), conclusion
Result of the test shows, compare with negative control group, the equal obviously dose dependent ground of compound recipe erdosteine ambroxol (mass ratio 2: 1) and ambroxol hydrochloride oral administration increases the secretion of rabbit respiratory tract sputum, and the secretory action of compound recipe erdosteine ambroxol (mass ratio 2: 1) increase sputum is strong than the ambroxol hydrochloride of Isodose.Erdosteine 4mg/kg oral administration also can obviously increase the secretion of rabbit respiratory tract sputum.
Test specimen is to the influence of rabbit expectorant sputum secretory volume (x ± s)
| Group | Dosage (mg/kg) | Secretory volume (g) | Rate of change (%) |
| Negative control compound Erdosteine ambroxol (mass ratio 2: 1) ambroxol hydrochloride Erdosteine | NS 1ml/kg 1 2 4 8 2 4 8 4 | 0.0452±0.0118 0.0608±0.0139 *0.0889±0.0276 ** 0.0941±0.0285 **0.1013±0.0218 **0.0624±0.0176 *0.0688±0.0135 **0.0844±0.0245 **0.0736±0.0216 ** | 34.5 96.6 108.1 124.0 38.0 52.0 86.5 62.8 |
3 pairs of Canis familiaris L. isolated tracheals of experimental example effect on ciliary movement
1), test method
About grass Canis familiaris L. 10kg, the male and female dual-purpose, the anesthesia back is separated trachea rapidly, puts logical O
2Tyrode's solution in, preserve standby.During experiment, clip trachea 0.5～1cm is long.The center is cut off, and vertically is divided into two, gets monolithic and tiltedly is put on the moistening Cotton Gossypii of 37 ℃ of tyrode's solutions (the larynx end up).(0.2mm) places the trachea lower end with hair, observe with low power microscope, and the record hair operation required time of 2mm, to observe 3 times, every observation 1 time is put into 37 ℃ of tyrode's solution rinsings with the trachea sheet.Put into the nutritional solution 5min that contains medicinal liquid then, observe 3 times with method.Calculate the administration front and back hair difference of running time, and compare with the feminine gender group.
2), statistical procedures
All data represent that with x ± S the statistical analysis of data is checked with t
3), result of the test
Following table result shows, compare with negative control group, compound recipe erdosteine ambroxol (etc. quality) is 0.5-1mg/ml and ambroxol hydrochloride in concentration in concentration is that 0.125-1mg/ml can shorten hair and moves the required time of 2mm, but because of individual variation is big, the compound recipe erdosteine ambroxol when only high concentration (1mg/ml) ambroxol hydrochloride is with 0.5mg/ml, concentration (etc. quality) is compared with matched group has significant difference (P＜0.05) statistically; 1.0mg/ml comparing with matched group, the compound recipe erdosteine ambroxol during concentration (etc. quality) has significant differences statistically (P＜0.01).
4), conclusion
Result of the test shows compound recipe erdosteine ambroxol (etc. quality) 0.5mg/ml and the ambroxol hydrochloride 1.0mg/ml Canis familiaris L. tracheal cilia motion of all obviously accelerating to exsomatize, the Canis familiaris L. tracheal cilia motion of very obviously accelerating to exsomatize during compound recipe erdosteine ambroxol (etc. quality) 1.0mg/ml concentration.And compound recipe erdosteine ambroxol (etc. quality) 0.5mg/ml and ambroxol hydrochloride 1.0mg/ml accelerate the to exsomatize effect of Canis familiaris L. tracheal cilia motion is suitable.
Compound recipe erdosteine ambroxol (etc. quality) to the Canis familiaris L. effect on ciliary movement (x ± s, n=12)
| Group | Drug level (mg/ml) | n | The administration time that moves forward and backward changes (s) |
| Matched group compound recipe erdosteine ambroxol (waiting mole) | - 0.125 0.25 0.5 1.0 0.5 | 12 12 12 12 12 12 | 3.17±5.59 -3.33±9.86 -2.08±7.03 -4.33±9.53 *-5.25±7.01 **-2.33±8.00 |
| Ambroxol hydrochloride ambroxol hydrochloride matched group relatively | 0.5 1.0 | 12 12 | -2.33±8.00 -4.50±7.83 * |
The antitussive effect of 4 pairs of ammonia inducing mouse coughs of experimental example
1), experimental technique
Given in 3 days in advance by the reagent thing.After 4 hours, each is organized medicine and irritates stomach by 0.2ml/10g volume per os in formal experiment mice fasting on the same day, the oral tragakanta 0.2ml/10g of blank group, and administration begins test after 1 hour.Experiment mice is put into inverted 500ml beaker, put into ammonia 2ml in the aerosol apparatus, nozzle stretches into 1cm in the beaker, atomisation pressure 50KPa, air mass flow 400ml/s, spraying 8s.Open greatly with the mice mouth, abdominal part acutely is punctured into cough, record spraying beginning is extremely coughed the time first as the number of times of coughing in cough latent period and the spraying back 5min, calculate the x ± s that respectively organizes incubation period and cough number of times, with the t method of inspection between group, each group mean is compared with the blank group.
2), experimental result
Experimental result sees the following form
Compound recipe erdosteine ambroxol (etc. quality) antitussive pharmacodynamic study (n=12, x ± s)
| Group | Dosage mg/kg | Cough latent period (s) | The cough number of times (inferior/5min) |
| The blank ambroxol hydrochloride | - 8 16 32 8 16 32 | 42.7±19.4 59.1±21.4 60.9±18.5 * 74.3±32.1 ** 60.8±30.4 74.3±32.4 ** 83.4±22.8 *** | 39.6±14.5 28.9±13.4 23.2±9.8 ** 20.7±8.2 ** 28.8±17.1 22.2±10.7 ** 18.7±11.5 *** |
● P＜0.05,
*P＜0.01,
* *P＜0.001 with the blank group relatively
The cough latent period that compound recipe erdosteine ambroxol (etc. quality) 8～32mg/kg can make ammonia bring out prolongs, and the cough number of times in the 5min is reduced, and all with the dosage positive correlation.Compound recipe erdosteine ambroxol (etc. quality) 16mg/kg, it is 74.3 ± 32.4s that ammonia draws the incubation period of coughing, with the blank group significant differences (P＜0.01) is arranged relatively, and the 32mg/kg group is 83.4 ± 22.8s incubation period, with the blank group significant differences (P＜0.001) is arranged relatively.Compound recipe erdosteine ambroxol (etc. quality) draws the preclinical prolongation effect coughed all greater than the ambroxol hydrochloride of Isodose to ammonia, and ambroxol hydrochloride high dose 32mg/kg is suitable to dosage 16mg/kg in the prolongation effect of cough latent period and the compound recipe erdosteine ambroxol (etc. quality).Reach identical prolongation effect compound erdosteine ambroxol (etc. quality) and only need half dosage of ambroxol hydrochloride.
The mouse cough number of times that compound recipe erdosteine ambroxol (etc. quality) 8～32mg/kg can make ammonia bring out reduces, and the degree and the dosage positive correlation that reduce.Compound recipe erdosteine ambroxol (etc. quality) 16mg/kg, the cough number of times that ammonia causes is 22.2 ± 10.7 times, with 39.6 ± 14.5 times of blank group significant differences (P＜0.01) is arranged relatively, compound recipe erdosteine ambroxol (etc. quality) 32mg/kg, the cough number of times that ammonia causes is 18.7 ± 11.5 times, with the blank group utmost point significant differences (P＜0.001) is arranged relatively.Compound recipe erdosteine ambroxol (etc. quality) 32mg/kg is better than the Isodose ambroxol hydrochloride to the minimizing effect of cough number of times.
3), conclusion
The mouse cough highly significant incubation period prolongation that compound recipe erdosteine ambroxol (etc. quality) 16～32mg/kg can make ammonia cause makes the minimizing of cough number of times highly significant.Compound recipe erdosteine ambroxol (etc. quality) draws the prolongation effect of coughing cough latent period to ammonia and is better than ambroxol hydrochloride.Compound recipe erdosteine ambroxol (etc. quality) 32mg/kg also is better than the ambroxol hydrochloride of Isodose to the minimizing effect of cough number of times.Compound recipe erdosteine ambroxol (etc. quality) has tangible antitussive effect, and antitussive effect is better than ambroxol hydrochloride.
Experimental example 5 compound recipe erdosteine ambroxol mice oral administration acute toxicity testings
1) given the test agent 1
Title: compound recipe erdosteine ambroxol
Source: Lianyun Harbour gloomy Pharmaceutical of person of outstanding talent limited company
Character: white powder crystallization
Solvent: 0.5% tragakanta
Preparation: after compound recipe erdosteine ambroxol (etc. quality) accurately taken by weighing, add the suspension that 0.5% tragakanta is diluted to 200mg/ml, and then press 1: 0.75 dilution proportion with 0.5% tragakanta
2) given the test agent 2
Title: ambroxol hydrochloride
Source: Lianyun Harbour gloomy Pharmaceutical of person of outstanding talent limited company
Character: white powder crystallization
Solvent: 0.5% tragakanta
Prepare: after ambroxol hydrochloride is accurately taken by weighing, add the suspension that 0.5% tragakanta is diluted to 200mg/ml, and then press 1: 0.75 dilution proportion with 0.5% tragakanta
3) laboratory animal and raising
Strain: Kunming mouse
Sex: male and female half and half
Body weight: 18-20g
The source: Shanghai Institute of Pharmaceutical Industry's Animal House provides
The quality certification number: SYXK (Shanghai) 2004-0015
Raise: animal feeding in positive pressure purification ventilation Animal House, 25 ± 2 ℃ of temperature, ad lib and drinking-water.
4) experimental technique
Animal is evenly divided into groups by body weight, each 10 animal of every dosage group male and female, all at 949～4000mg/kg, dosage was in ratio setting in 1: 75 through the dosage range of selected female, the male mice of prerun.Fasting is 4 hours before the zoopery.The administration group is pressed the heavy every 0.2ml/10g volume of animal body and is irritated the appetite clothes, matched group gives 0.5% tragakanta solution of Isodose, observe reaction of animals after the administration continuously, and animal dead number in record 1h, 2h, 4h, 1d, 2d, 3d to the 14d equal time, dead animal is carried out each main organs situation of anatomic observation, and surviving animals was dissected at the 7th day.Each dosage treated animal death toll is calculated other LD of male and female two individual characteies with bliss method in the Ministry of Public Health new drug statistical procedure
50(95% fiducial limit) value.
5) experimental result
Behind the mice oral administered compound erdosteine ambroxol (etc. quality), promptly occur after 5 minutes prostrate, turn round body, startle, twitch until death, individual animal also occurs spinning and the death of tetanic property, no convulsions phenomenon takes place.Except that 3000 and each 1 animal of 1688mg/kg group between 4～24 hours the death, all the other animal deads are all after administration in 1 hour.Each dosage group existence animals administer recovered normal activity after 1 day.Existence and dead animal show no obvious abnormalities through each main organs of anatomic observation.The LD that calculates with the Bliss method
50(95% fiducial limit) is female to be 2254.88 (1897.32～2725.56) mg/kg, and male is 2195.44 (1837.46～2664.75), two kinds of sex LD of male and female
50Be worth no significant difference (p＞0.05).
Behind the ambroxol hydrochloride oral, reaction symptom of animal and death condition and compound recipe erdosteine ambroxol (etc. quality) are similar, the LD that calculates with the Bliss method
50(95% fiducial limit) is female to be 1512.22 (1310.70～1738.07) mg/kg, and male is 1547.29 (1329.17～1793.42) mg/kg.Two kinds of sex LD of male and female
50Be worth no significant difference (p＞0.05)
Embodiment 1:
Ambroxol 30mg
Erdosteine 150mg
Microcrystalline Cellulose 27.5mg
Lactose fruit monohydrate is an amount of
Magnesium stearate 0.5mg
Every 208mg
After pressing above-mentioned raw materials, adjuvant mix homogeneously, according to conventional wet granulation, drying, tabletting.
Embodiment 2:
Ambroxol 30mg
Acetylcysteine 30mg
NaCl 0.9g
Water for injection is an amount of
Every 100ml
Get sodium chloride, use the water for injection stirring and dissolving, add ambroxol, acetylcysteine then respectively, continue to stir to make fully and dissolve, add water for injection, filter to clear and bright to total amount, embedding, sterilization, promptly.
Embodiment 3:
The slow-release micro-pill preparation
Slow-released part prescription (ball 1)
Ball core prescription
Ambroxol 30g
Erdosteine 150g
Microcrystalline Cellulose 15g
Hypromellose 5g
Pure water 200ml
Make 1000
The coating prescription
25% ethyl cellulose aqueous dispersions 184g
Pure water 123g
Make 1000
Respectively microcrystalline Cellulose, ambroxol, erdosteine were pulverized 100 mesh sieves in advance, took by weighing by ball 1 prescription, mix homogeneously, the hydroxypropyl methylcellulose aqueous solution is done binding agent, and the system micropill in 50～60 ℃ of dryings, selects 20～30 purpose pillers with it, and is standby.
With the micropill for preparing and choose, put in the fluid bed, adopt end spray mode, by hot-air suspension fluidisation, inlet temperature is 55 ℃, when the material bed tempertaure is controlled at 30 ℃, regulates peristaltic pump and make its speed provide coating solution, atomizing pressure 2bar by per minute 5g serosity, begin fluidizing piller is whitewashed continuously, after whitewashing finishes, reduce air quantity, make micropill for a moment dry in 40 ℃ under slight boiling condition.Taking-up was placed in 40 ℃ of baking ovens dry 24 hours, and it is about 18% to increase weight, and measures content, promptly.
The configuration of medicine box
Medicine box a kind of use clinically or that family uses, wherein dispose the tablet of two kinds or three kinds medicines, it is ambroxol, its content is 1-2000mg and erdosteine, its content is 1-2000mg, perhaps ambroxol, its content is 1-2000mg and acetylcysteine, its content is 1-2000mg.
Those skilled in the art adopt known method can finish the configuration of the present composition in conjunction with the content of above-mentioned disclosure.
Claims (7)
1. one kind is used to prevent and treat various inflammation and the expectorant pharmaceutical composition that respiratory tract is congested and infect, described pharmaceutical composition comprises the ambroxol of pharmaceutically acceptable form and is selected from the another kind of medicine of erdosteine or acetylcysteine, wherein, the content of ambroxol is 1-2000mg, the content of erdosteine is 1-2000mg, and the content of acetylcysteine is 1-2000mg.
2. pharmaceutical composition according to claim 1, described ambroxol are alkali or its officinal salt.
3. pharmaceutical composition according to claim 1, wherein ambroxol, erdosteine or acetylcysteine adopt separately independently medicine type respectively.
4. pharmaceutical composition according to claim 1 and 2, the dosage form of its pharmaceutical composition are injection, spray, tablet, slow releasing agent, drop pill, granule or capsule.
5. the application of pharmaceutical composition according to claim 1 and 2 in preparation expectorant medicine.
6. a medicine box is characterized in that containing ambroxol and erdosteine or their pharmaceutically acceptable salt, and wherein, the content of ambroxol is 1-2000mg, and the content of erdosteine is 1-2000mg.
7. a medicine box is characterized in that containing ambroxol and acetylcysteine or their pharmaceutically acceptable salt, and wherein, the content of ambroxol is 1-2000mg, and the content of acetylcysteine is 1-2000mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100775504A CN1323662C (en) | 2004-06-18 | 2005-06-17 | Pharmaceutical composition containing ambroxol and erdosteine or acetylcysteine and application thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410048798 | 2004-06-18 | ||
| CN200410048798.3 | 2004-06-18 | ||
| CNB2005100775504A CN1323662C (en) | 2004-06-18 | 2005-06-17 | Pharmaceutical composition containing ambroxol and erdosteine or acetylcysteine and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1720911A CN1720911A (en) | 2006-01-18 |
| CN1323662C true CN1323662C (en) | 2007-07-04 |
Family
ID=35911750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100775504A Expired - Fee Related CN1323662C (en) | 2004-06-18 | 2005-06-17 | Pharmaceutical composition containing ambroxol and erdosteine or acetylcysteine and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1323662C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101214227B (en) * | 2007-12-29 | 2013-06-19 | 沈阳药科大学 | Ambroxol hydrochloride dry powder inhalant and preparation thereof |
| CN101606931B (en) * | 2009-08-06 | 2011-06-15 | 山东罗欣药业股份有限公司 | Erdosteine composition and preparation method thereof |
| CN105055348A (en) * | 2015-07-30 | 2015-11-18 | 青岛蓝盛洋医药生物科技有限责任公司 | Medicinal erdosteine composition tablet for treating respiratory tract inflammation and preparation method of tablet |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2083749A (en) * | 1980-09-17 | 1982-03-31 | Thomae Gmbh Dr K | Drug combination comprising ambroxol and an antibiotic for the treatment of infectious diseases of the respiratory tract |
| DE3530761A1 (en) * | 1985-08-28 | 1987-03-05 | Klinge Co Chem Pharm Fab | Pharmaceutical combination having synergistic action |
| CN1130354A (en) * | 1993-09-07 | 1996-09-04 | 普罗克特和廿保尔公司 | Composition comprising propionate NSAID amino acid salt and at least one of decongestant, expectorant, antihistamine and antitussive |
| JP2002363072A (en) * | 2001-04-03 | 2002-12-18 | Taisho Pharmaceut Co Ltd | Antitussive composition |
| CN1422162A (en) * | 2000-03-30 | 2003-06-04 | 先灵公司 | Composition and method for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant |
-
2005
- 2005-06-17 CN CNB2005100775504A patent/CN1323662C/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2083749A (en) * | 1980-09-17 | 1982-03-31 | Thomae Gmbh Dr K | Drug combination comprising ambroxol and an antibiotic for the treatment of infectious diseases of the respiratory tract |
| DE3530761A1 (en) * | 1985-08-28 | 1987-03-05 | Klinge Co Chem Pharm Fab | Pharmaceutical combination having synergistic action |
| CN1130354A (en) * | 1993-09-07 | 1996-09-04 | 普罗克特和廿保尔公司 | Composition comprising propionate NSAID amino acid salt and at least one of decongestant, expectorant, antihistamine and antitussive |
| CN1422162A (en) * | 2000-03-30 | 2003-06-04 | 先灵公司 | Composition and method for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant |
| JP2002363072A (en) * | 2001-04-03 | 2002-12-18 | Taisho Pharmaceut Co Ltd | Antitussive composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1720911A (en) | 2006-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1195511C (en) | The use of fumaric acid derivatives in transplant medicine | |
| JP2017061561A (en) | Controlled release pharmaceutical formulations of nitazoxanide | |
| CN1257422A (en) | Solid pharmaceutical preparation | |
| CN104068306B (en) | Health food for improving bone density and preparation method of health food | |
| CN1907358A (en) | Pharmaceutical composition for preventing and treating avian coccidiosis and its preparing method | |
| CN1921836A (en) | Multiparticulate formulations for oral delivery | |
| CN1809377A (en) | Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form | |
| CN1051550C (en) | 4- [ 2-amino-6- (cyclopropylamino) -9H-purin-9-yl ] -2-cyclopentene-1-methanol succinate as antiviral agent | |
| CN1943675A (en) | Tibetan medicinal composition for expectorant, antitussive, antiasthmatic and its preparation method | |
| CN1323662C (en) | Pharmaceutical composition containing ambroxol and erdosteine or acetylcysteine and application thereof | |
| JP6444515B2 (en) | Application of taurine in the prevention and / or treatment of diseases caused by coronavirus and / or rotavirus viruses | |
| CN1225464C (en) | Extraction process, medicinal composition and preparation process of wogonin | |
| CN1303065C (en) | Ambroxol cysteine analogs and their preparation process and use thereof | |
| CN1263464C (en) | Cathartic | |
| CN1857241A (en) | Medicine composition for treating productive cough and its use | |
| CN1915216A (en) | New usage of tandospirone and its derivative, and composition containing tandospirone | |
| CN1241562C (en) | Application of forsythin in the process for preparing adiposis treating oral medicine and healthy food | |
| CN1179726C (en) | Application of naringin in preparation of medicine for supportive treatment of atypical pneumonia | |
| CN1168496C (en) | Powder mist for pulmonary administration of insulin and preparation method thereof | |
| CN1404831A (en) | Use of Radix scutellariae glycoside in preparing medicine for treating prostatic disorders and its medicinal composition | |
| CN104208089B (en) | Gastric floating preparation for treating poultry proventriculitis and preparation method thereof | |
| CN102379920A (en) | Veterinary antiviral and antifebrile drug composition | |
| CN1439360A (en) | Dry powder composition for improvement of effective position medical deposit | |
| CN100349611C (en) | Redfish calcitonin inhalation powder-atomizing agent and preparing method | |
| CN1270776C (en) | Ulcer quieting medicine its preparation and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070704 Termination date: 20150617 |
|
| EXPY | Termination of patent right or utility model |